There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jasper Therapeutics (JSPR – Research Report), Alphatec Holdings (ATEC – Research Report) and TELA Bio (TELA – Research Report) with bullish sentiments.
Alphatec Holdings (ATEC)
In a report released today, Brooks O’Neil from Lake Street maintained a Buy rating on Alphatec Holdings, with a price target of $32.00. The company’s shares closed last Tuesday at $14.15.
According to TipRanks.com, O’Neil is a 3-star analyst with an average return of
Currently, the analyst consensus on Alphatec Holdings is a Strong Buy with an average price target of $23.28, which is a 72.6% upside from current levels. In a report issued on March 10, Wells Fargo also maintained a Buy rating on the stock with a $26.00 price target.
TELA Bio (TELA)
Lake Street analyst Frank Takkinen reiterated a Buy rating on TELA Bio today and set a price target of $14.00. The company’s shares closed last Tuesday at $5.35, close to its 52-week low of $4.23.
According to TipRanks.com, Takkinen is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TELA Bio with a $14.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on JSPR:
- Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
- Jasper announces first patient dosed in Phase 1b/2a SPOTLIGHT study
- Jasper Therapeutics initiated with an Outperform at TD Cowen
- Jasper Therapeutics presents Phase 1b/2a data on briquilimab
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
